<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279201</url>
  </required_header>
  <id_info>
    <org_study_id>10455</org_study_id>
    <secondary_id>F3Z-US-IOOV</secondary_id>
    <nct_id>NCT00279201</nct_id>
  </id_info>
  <brief_title>The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)</brief_title>
  <acronym>IOOV</acronym>
  <official_title>The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare insulin lispro low mixture [LM] and insulin glargine both in
      combination with the patient's oral diabetes medicines, for their ability to control blood
      sugar in patients with type 2 diabetes and compare insulin lispro LM to insulin glargine with
      regard to the length of time that the overall blood sugar can be controlled.

      This study will also determine whether the safety of insulin lispro LM and any side effects
      that might be associated with it are different from those observed with insulin glargine,
      both in combination with the patient's oral diabetes medications.

      The addendum study (Intensification Addendum) will compare how different insulin treatments
      work to control blood sugar in patients whose diabetes could not be controlled by either
      insulin lispro LM or insulin glargine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix)</measure>
    <time_frame>Endpoint (Last Observation Carried Forward [LOCF]) (Maintenance: up to 2.5 years)</time_frame>
    <description>HbA1c goal: HbA1c ≤7.0% or HbA1c &gt;7.0% but increased &lt;0.4% from last HbA1c ≤7.0%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADDENDUM: 24-Week Endpoint HbA1c</measure>
    <time_frame>Endpoint (Addendum) (24 weeks: Week 48)</time_frame>
    <description>HbA1c at 24-week endpoint in Intensification Addendum of the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Change in HbA1c From Baseline to 24 Weeks</measure>
    <time_frame>Baseline (Initiation) to Endpoint (LOCF, Week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt;7.0%, and HbA1c &lt; or = 6.5% at Endpoint</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: HbA1c</measure>
    <time_frame>Baseline (Initiation), Week 12, Week 24, Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions</measure>
    <time_frame>Endpoint (LOCF) (Initiation: Week 24)</time_frame>
    <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Change From Baseline to Endpoint in 1,5 Anhydroglucitol (1,5 AG)</measure>
    <time_frame>Baseline (Initiation), Endpoint (Week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Incremental Change From Baseline in Body Weight</measure>
    <time_frame>Baseline (Initiation), Weeks 6, 12, 18, 24, Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Body Weight</measure>
    <time_frame>Baseline (Initiation), Weeks 6, 12, 18, 24, Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Baseline (Initiation), Endpoint (Week 24), Overall (sum of frequencies of hypoglycemic episodes after baseline ([Week 0]).</time_frame>
    <description>Hypoglycemia = any time participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Rate of Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Endpoint (Initiation: Week 24), Overall (incidence of hypoglycemic episodes after baseline [Week 0])</time_frame>
    <description>Hypoglycemia = participant feels/person observes, that participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Insulin Dose</measure>
    <time_frame>Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of age at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of origin at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of HOMA-IR (surrogate markers of insulin resistance calculated from fasting insulin and glucose) at baseline between those participants who met their goal at Week 24 and those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%). HOMA-IR = fasting insulin (milliunits per milliliter) * fasting plasma glucose (millimoles per liter) / 22.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of baseline HbA1c between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of baseline HbA1c percentage group (&lt;8.5,&gt;=8.5) between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 1,5 AG</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of 1,5 AG between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose, Post Meals Blood Glucose, Average of All Blood Glucose, and Fasting Blood Glucose</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of pre meals blood glucose, post meals blood glucose, average of all blood glucose, and fasting blood glucose between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline</measure>
    <time_frame>Endpoint (Initiation: Week 24)</time_frame>
    <description>Comparison of oral diabetes medication at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: HbA1c at Specified Visits and Endpoint</measure>
    <time_frame>Baseline (Week 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions</measure>
    <time_frame>Baseline (Maintenance: Week 24), Endpoint (LOCF) (up to 2.5 years)</time_frame>
    <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Rate of Increase in HbA1c</measure>
    <time_frame>Endpoint (LOCF) (Maintenance: up to 2.5 years)</time_frame>
    <description>Rate of increase: HbA1c change/time period (month).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt;7.0, and HbA1c &lt; or = 6.5%</measure>
    <time_frame>Endpoint (LOCF) (Maintenance: up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Incremental Change From Baseline in Body Weight</measure>
    <time_frame>Baseline (Week 0), Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Body Weight</measure>
    <time_frame>Baseline (Week 0), Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Insulin Dose</measure>
    <time_frame>Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years), Overall (incidence of hypoglycemic episodes after baseline (Week 0)</time_frame>
    <description>Hypoglycemia = participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years), Overall (incidence of hypoglycemic episodes after baseline [Week 0])</time_frame>
    <description>Hypoglycemia = participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Change From Baseline in 1,5-Anhydroglucitol</measure>
    <time_frame>Baseline (Maintenance: Week 24), Endpoint (LOCF) (up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Change From Baseline to Endpoint in HbA1c</measure>
    <time_frame>Baseline (Week 0), Week 24, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of duration of diabetes at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of duration of diabetes at baseline between those participants taking lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of duration of diabetes group (&lt;10, 10-&lt;20, &gt;=20 years) at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of duration of diabetes group (&lt;10, 10-&lt;20, &gt;=20 years) at baseline between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline HbA1c between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline HbA1c between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline HbA1c group (&lt;8.5,&gt;=8.5) between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline HbA1c group (&lt;8.5,&gt;=8.5) between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of oral diabetes medication at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of oral diabetes medication at baseline between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline 1,5 AG between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline 1,5 AG between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline mean of post meals blood glucose and average of all blood glucose between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose</measure>
    <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
    <description>Comparison of baseline mean of post meals blood glucose and average of all blood glucose between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint</measure>
    <time_frame>Baseline (Addendum: Week 24), Endpoint (24 weeks [Week 48])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt; 7.0%, and &lt; or = 6.5%</measure>
    <time_frame>Endpoint (Addendum: 24 weeks [Week 48])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: 7-point SMPG Profiles</measure>
    <time_frame>Endpoint (Addendum: 24 weeks [Week 48])</time_frame>
    <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Incremental Change From Baseline in Body Weight</measure>
    <time_frame>Baseline (Addendum: Week 24), Weeks 6 (30 Weeks), 12 (36 Weeks), 24 (48 Weeks), Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Body Weight</measure>
    <time_frame>Baseline (Addendum Week 24), Weeks 6 (30 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Insulin Dose</measure>
    <time_frame>Baseline (Addendum: Week 24), Weeks 1 (25 weeks), 2 (26 weeks), 3 (27 weeks), 4 (28 weeks), 5 (25 weeks), 6 (26 weeks), 8 (32 weeks), 10 (34 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Weeks 6 (Addendum: 30 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)</time_frame>
    <description>Hypoglycemia = any time participant feels/person observes, that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Rate of Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Endpoint (Addendum 24 weeks), Overall (mean yearly rate of hypoglycemia during addendum phase</time_frame>
    <description>Hypoglycemia = participant feels/person observes, that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: Change From Baseline in 1,5-Anhydroglucitol to Week 24</measure>
    <time_frame>Baseline (addendum: 24 weeks), Endpoint (24 weeks: Week 48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADDENDUM: HbA1c at Specified Visits and Endpoint</measure>
    <time_frame>Baseline (Addendum: 24 weeks), Weeks 12, 24, Endpoint (24 weeks: Week 48)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">2091</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lispro Low Mix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lispro Mid Mix prior Lispro Low Mix addendum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lispro Low Mix prior Glargine addendum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal bolus prior Lispro Low Mix addendum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal bolus prior Glargine addendum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Subcutaneous injection daily</description>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_label>Basal bolus prior Lispro Low Mix addendum</arm_group_label>
    <arm_group_label>Basal bolus prior Glargine addendum</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lispro Low Mix</intervention_name>
    <description>Subcutaneous injection twice daily.</description>
    <arm_group_label>Lispro Low Mix</arm_group_label>
    <arm_group_label>Lispro Low Mix prior Glargine addendum</arm_group_label>
    <other_name>Humalog Mix 75/25</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lispro Mid Mix</intervention_name>
    <description>Lispro Mid Mix subcutaneous injection 3 times daily.</description>
    <arm_group_label>Lispro Mid Mix prior Lispro Low Mix addendum</arm_group_label>
    <other_name>Humalog Mix 50/50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lispro</intervention_name>
    <description>Lispro subcutaneous injection 3 times daily.</description>
    <arm_group_label>Basal bolus prior Lispro Low Mix addendum</arm_group_label>
    <arm_group_label>Basal bolus prior Glargine addendum</arm_group_label>
    <other_name>Humalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have type 2 diabetes.

          -  Must be at least 30 and less than 80 years of age at the time of Visit 1.

          -  Must be on at least two oral antidiabetes medications for at least 90 days.

          -  Must have an HbA1c 1.2 to 2.0 times the upper limit of normal reference range at the
             local lab.

        Exclusion Criteria:

          -  Must not have used insulin on a regular basis in the last 12 months.

          -  Must not have had more than one episode of severe hypoglycemia in the last 24 weeks.

          -  Must not have a body mass index (BMI) of greater than 45 (morbid obesity).

          -  Must not have clinically significant hematologic, oncologic, renal, cardiac, hepatic,
             or gastrointestinal disease.

          -  Must not be pregnant or intend to get pregnant during course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kellogg</city>
        <state>Idaho</state>
        <zip>83837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belleville</city>
        <state>Illinois</state>
        <zip>62220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Reisterstown</city>
        <state>Maryland</state>
        <zip>21136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <zip>08084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mamaroneck</city>
        <state>New York</state>
        <zip>10543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Massapequa</city>
        <state>New York</state>
        <zip>11758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Hartford</city>
        <state>New York</state>
        <zip>13413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tabor City</city>
        <state>North Carolina</state>
        <zip>28463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jamestown</city>
        <state>North Dakota</state>
        <zip>58401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ohio</state>
        <zip>43140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <zip>19522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Levittown</city>
        <state>Pennsylvania</state>
        <zip>19056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hartsville</city>
        <state>South Carolina</state>
        <zip>29550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1188AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pilar</city>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingswood Penrith</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Keswick</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burnie</city>
        <state>Tasmania</state>
        <zip>7320</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Setor Oeste/Goiania</city>
        <zip>74043-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 0M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N 6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petitcodiac</city>
        <state>New Brunswick</state>
        <zip>E4Z 4R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2G 5X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nikaias - Piraeus</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pecs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahemdabad</city>
        <zip>380013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aligarh</city>
        <zip>202002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Karnal/Haryana</city>
        <zip>132 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trivandrum</city>
        <zip>695029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brunssum</city>
        <zip>6442 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Emmen</city>
        <zip>7824 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bayamon</city>
        <zip>00959</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orcorvis</city>
        <zip>00720</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponce</city>
        <zip>00717-2075</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>70266</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>3400</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>1900</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alcira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dos Hermanas</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mosteles</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Requena</city>
        <zip>46340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <results_reference>
    <citation>Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H, Martin S. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 May;94(5):1689-94. doi: 10.1210/jc.2008-1940. Epub 2009 Mar 10.</citation>
    <PMID>19276235</PMID>
  </results_reference>
  <results_reference>
    <citation>Fahrbach J, Jacober S, Jiang H, Martin S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol. 2008 Sep;2(5):831-8.</citation>
    <PMID>19885269</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2005</study_first_submitted>
  <study_first_submitted_qc>January 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2006</study_first_posted>
  <results_first_submitted>November 11, 2010</results_first_submitted>
  <results_first_submitted_qc>January 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2011</results_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Initiation: Glargine or Lispro LM - 24 weeks. Maintenance: Up to 2 more years treatment if HbA1c &lt;=7.0 at 24 weeks. After Initiation, if HbA1c &gt;7.0 after 24 weeks, instead of entering Maintenance, those from Lispro LM could receive Basal bolus or Mid Mix; glargine could receive Basal bolus or Lispro LM for 24 weeks in Intensification Addendum.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine</title>
          <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Lispro Low Mix</title>
          <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
          <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
        </group>
        <group group_id="P4">
          <title>Lispro Low Mix Prior Glargine Addendum</title>
          <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase.</description>
        </group>
        <group group_id="P5">
          <title>Basal Bolus Prior Lispro Low Mix Addendum</title>
          <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
        </group>
        <group group_id="P6">
          <title>Basal Bolus Prior Glargine Addendum</title>
          <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initiation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1046"/>
                <participants group_id="P2" count="1045"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="918"/>
                <participants group_id="P2" count="900"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Exclusion</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation Oral Antihyperglycemics</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="419">100 left the study after initiation. 399 had HbA1c&gt;7% and enrolled in intensification addendum.</participants>
                <participants group_id="P2" count="473">82 left the study after initiation. 345 had HbA1c&gt;7% and enrolled in intensification addendum.</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="239"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="234"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation Antihyperglycemic Drugs</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Exclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HbA1c&gt;7.5%</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intensification Addendum</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="174"/>
                <participants group_id="P4" count="200"/>
                <participants group_id="P5" count="171"/>
                <participants group_id="P6" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="172"/>
                <participants group_id="P5" count="142"/>
                <participants group_id="P6" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Glargine</title>
          <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Lispro LM</title>
          <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1046"/>
            <count group_id="B2" value="1045"/>
            <count group_id="B3" value="2091"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.59" spread="9.95"/>
                    <measurement group_id="B2" value="57.05" spread="9.73"/>
                    <measurement group_id="B3" value="56.82" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="552"/>
                    <measurement group_id="B3" value="1104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="668"/>
                    <measurement group_id="B2" value="651"/>
                    <measurement group_id="B3" value="1319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African Descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East/Southeast Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                    <measurement group_id="B2" value="513"/>
                    <measurement group_id="B3" value="1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.23" spread="20.78"/>
                    <measurement group_id="B2" value="88.84" spread="20.97"/>
                    <measurement group_id="B3" value="88.53" spread="20.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilograms per meters squared (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.69" spread="6.01"/>
                    <measurement group_id="B2" value="31.67" spread="5.96"/>
                    <measurement group_id="B3" value="31.68" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.30" spread="5.93"/>
                    <measurement group_id="B2" value="9.73" spread="6.29"/>
                    <measurement group_id="B3" value="9.51" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.02" spread="1.24"/>
                    <measurement group_id="B2" value="9.06" spread="1.29"/>
                    <measurement group_id="B3" value="9.04" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>1,5 Anhydroglucitol (1,5 AG)</title>
          <units>micrograms per milliliter (ug/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.97" spread="4.06"/>
                    <measurement group_id="B2" value="5.02" spread="4.12"/>
                    <measurement group_id="B3" value="4.99" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean of Pre-Meals Blood Glucose</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201.29" spread="57.40"/>
                    <measurement group_id="B2" value="198.97" spread="54.87"/>
                    <measurement group_id="B3" value="200.13" spread="56.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean of Post Meals Blood Glucose (Postprandial)</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241.58" spread="61.06"/>
                    <measurement group_id="B2" value="240.08" spread="58.15"/>
                    <measurement group_id="B3" value="240.82" spread="59.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average of All Blood Glucose</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218.05" spread="56.55"/>
                    <measurement group_id="B2" value="216.12" spread="54.40"/>
                    <measurement group_id="B3" value="217.08" spread="55.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Blood Glucose</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196.16" spread="55.14"/>
                    <measurement group_id="B2" value="192.91" spread="53.22"/>
                    <measurement group_id="B3" value="194.53" spread="54.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c)</title>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment in the initiation phase. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c)</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment in the initiation phase. Initiation baseline: Week 0.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="1.07"/>
                    <measurement group_id="O2" value="7.23" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA, baseline value as covariate. Response = Treatment + Baseline + Country + thiazolidinedione (TZD) use + Sulfonylurea (sulfo) use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix)</title>
        <description>HbA1c goal: HbA1c ≤7.0% or HbA1c &gt;7.0% but increased &lt;0.4% from last HbA1c ≤7.0%</description>
        <time_frame>Endpoint (Last Observation Carried Forward [LOCF]) (Maintenance: up to 2.5 years)</time_frame>
        <population>Last observation carried forward method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix)</title>
          <description>HbA1c goal: HbA1c ≤7.0% or HbA1c &gt;7.0% but increased &lt;0.4% from last HbA1c ≤7.0%</description>
          <population>Last observation carried forward method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.40" lower_limit="13.40" upper_limit="16.83"/>
                    <measurement group_id="O2" value="16.80" lower_limit="14.03" upper_limit="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by country, thiazolidinedione (TZD) use, sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ADDENDUM: 24-Week Endpoint HbA1c</title>
        <description>HbA1c at 24-week endpoint in Intensification Addendum of the trial.</description>
        <time_frame>Endpoint (Addendum) (24 weeks: Week 48)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: Week 24: 48 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro LM Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: 24-Week Endpoint HbA1c</title>
          <description>HbA1c at 24-week endpoint in Intensification Addendum of the trial.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: Week 24: 48 weeks.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="1.26"/>
                    <measurement group_id="O2" value="8.03" spread="1.15"/>
                    <measurement group_id="O3" value="8.16" spread="1.43"/>
                    <measurement group_id="O4" value="8.14" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.990</p_value>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Change in HbA1c From Baseline to 24 Weeks</title>
        <time_frame>Baseline (Initiation) to Endpoint (LOCF, Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Change in HbA1c From Baseline to 24 Weeks</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="977"/>
                <count group_id="O2" value="962"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.27"/>
                    <measurement group_id="O2" value="-1.83" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt;7.0%, and HbA1c &lt; or = 6.5% at Endpoint</title>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt;7.0%, and HbA1c &lt; or = 6.5% at Endpoint</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for &lt;=7.0%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for &lt;7.0%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>P-value is for &lt;=6.5%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: HbA1c</title>
        <time_frame>Baseline (Initiation), Week 12, Week 24, Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: HbA1c</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1030"/>
                <count group_id="O2" value="1017"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1030,1017)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02" spread="1.24"/>
                    <measurement group_id="O2" value="9.06" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=952,953)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="0.95"/>
                    <measurement group_id="O2" value="7.27" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=922,911)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" spread="1.06"/>
                    <measurement group_id="O2" value="7.19" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (LOCF) (n=990,986)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="1.07"/>
                    <measurement group_id="O2" value="7.23" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.416</p_value>
            <p_value_desc>P-value for baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value for endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions</title>
        <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
        <time_frame>Endpoint (LOCF) (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions</title>
          <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>milligrams per 100 Milliliters (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="989"/>
                <count group_id="O2" value="995"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline mean fasting blood glucose (n=986,993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.16" spread="55.14"/>
                    <measurement group_id="O2" value="192.91" spread="53.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean fasting blood glucose (n=938,922)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.52" spread="33.41"/>
                    <measurement group_id="O2" value="133.54" spread="35.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM 2-hour postprandial BG (n=977,989)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.45" spread="64.78"/>
                    <measurement group_id="O2" value="252.46" spread="64.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM 2-hour postprandial blood glucose (n=932,920)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.79" spread="49.14"/>
                    <measurement group_id="O2" value="167.40" spread="49.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline midday premeal BG (n=976,988)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.87" spread="67.31"/>
                    <measurement group_id="O2" value="203.76" spread="65.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midday premeal blood glucose (BG) (n=934,919)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.43" spread="44.05"/>
                    <measurement group_id="O2" value="130.36" spread="42.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline midday 2-hour postprandial BG (n=974,988)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.73" spread="68.84"/>
                    <measurement group_id="O2" value="231.53" spread="66.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midday 2-hour postprandial BG (n=929,916)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.38" spread="46.78"/>
                    <measurement group_id="O2" value="167.91" spread="48.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline evening pre-meal BG (n=983,993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.33" spread="66.50"/>
                    <measurement group_id="O2" value="200.36" spread="64.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening pre-meal blood glucose (n=936,922)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.86" spread="45.44"/>
                    <measurement group_id="O2" value="143.44" spread="43.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline evening 2hour postprandial BG (n=983,991)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.73" spread="70.28"/>
                    <measurement group_id="O2" value="236.33" spread="64.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening 2-hour postprandial BG (n=932,921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.73" spread="48.66"/>
                    <measurement group_id="O2" value="163.20" spread="46.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 3 AM blood glucose (n=955,975)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.99" spread="64.28"/>
                    <measurement group_id="O2" value="194.11" spread="61.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 AM blood glucose (n=912,899)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.08" spread="42.38"/>
                    <measurement group_id="O2" value="129.70" spread="40.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM 2-hour BG excursion (n=975,987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.32" spread="46.93"/>
                    <measurement group_id="O2" value="60.06" spread="47.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM 2-hour blood glucose excursion (n=932,920)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.57" spread="43.59"/>
                    <measurement group_id="O2" value="34.01" spread="45.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline midday 2-hour BG excursion (n=966,981)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.60" spread="48.50"/>
                    <measurement group_id="O2" value="28.08" spread="45.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midday 2-hour blood glucose excursion (n=928,916)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.21" spread="40.40"/>
                    <measurement group_id="O2" value="37.46" spread="44.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PM 2-hour BG excursion (n=979,988)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.50" spread="46.11"/>
                    <measurement group_id="O2" value="36.31" spread="44.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM 2-hour blood glucose excursion (n=929,921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.17" spread="40.30"/>
                    <measurement group_id="O2" value="19.51" spread="42.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all meal time excursions (n=985,991)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.80" spread="29.92"/>
                    <measurement group_id="O2" value="41.63" spread="28.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean of all meal time excursions (n=935,921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.96" spread="27.22"/>
                    <measurement group_id="O2" value="30.34" spread="28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all 2hour PP BG (n=986,993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.58" spread="61.06"/>
                    <measurement group_id="O2" value="240.08" spread="58.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean of all 2-hour postprandial BG (n=935,921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.28" spread="41.04"/>
                    <measurement group_id="O2" value="166.17" spread="39.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM/PM 2-hour postprandial BG (n=986,993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.67" spread="62.02"/>
                    <measurement group_id="O2" value="244.36" spread="59.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM/PM 2-hour postprandial BG (n=935,921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.73" spread="42.83"/>
                    <measurement group_id="O2" value="165.19" spread="41.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all premeal BG (n=988,994)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.29" spread="57.40"/>
                    <measurement group_id="O2" value="198.97" spread="54.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean of all premeal blood glucose (n=938,922)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.62" spread="34.09"/>
                    <measurement group_id="O2" value="135.80" spread="32.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM/PM 2-hour BG excursion (n=985,991)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.05" spread="35.06"/>
                    <measurement group_id="O2" value="48.11" spread="35.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM/PM 2-hour blood glucose excursion (n=935,921)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.42" spread="31.96"/>
                    <measurement group_id="O2" value="26.74" spread="34.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean of all BG values (n=989,995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.05" spread="56.55"/>
                    <measurement group_id="O2" value="216.12" spread="54.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean of all blood glucose values (n=938,922)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.89" spread="34.32"/>
                    <measurement group_id="O2" value="147.96" spread="32.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <p_value_desc>P-value is for Baseline mean fasting blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for mean fasting blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.700</p_value>
            <p_value_desc>P-value is for Baseline AM 2-hour postprandial BG.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>P-value for AM 2-hour postprandial blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.971</p_value>
            <p_value_desc>P-value is for Baseline midday premeal BG.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Midday premeal blood glucose (BG).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.759</p_value>
            <p_value_desc>P-value is for Baseline midday 2-hour postprandial BG</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.514</p_value>
            <p_value_desc>P-value Midday 2-hour postprandial BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.321</p_value>
            <p_value_desc>P-value is for Baseline evening pre-meal BG.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.161</p_value>
            <p_value_desc>P-value for Evening pre-meal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.297</p_value>
            <p_value_desc>P-value is for Baseline evening 2hour postprandial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value Evening 2-hour postprandial BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <p_value_desc>P-value is for Baseline 3 AM blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.693</p_value>
            <p_value_desc>P-value is for 3 AM blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value is for Baseline AM 2-hour BG excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for AM 2-hour blood glucose excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.567</p_value>
            <p_value_desc>P-value is for Baseline midday 2-hour BG excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value is for Midday 2-hour blood glucose excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.994</p_value>
            <p_value_desc>P-value is for Baseline PM 2-hour BG excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PM 2-hour blood glucose excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.436</p_value>
            <p_value_desc>P-value is for Baseline mean all meal time excursions.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Mean of all meal time excursions.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.628</p_value>
            <p_value_desc>P-value is for Baseline mean all 2hour PP BG.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Mean of all 2-hour postprandial BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <p_value_desc>P-value is for Baseline AM/PM 2-hour postprandial BG.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for AM/PM 2-hour postprandial BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.364</p_value>
            <p_value_desc>P-value is for Baseline mean all premeal BG.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>P-value is for Mean of all premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.165</p_value>
            <p_value_desc>P-value is for Baseline AM/PM 2-hour BG excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for AM/PM 2-hour blood glucose excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.464</p_value>
            <p_value_desc>P-value is for Baseline mean of all BG values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.305</p_value>
            <p_value_desc>P-value is for Mean of all blood glucose values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Change From Baseline to Endpoint in 1,5 Anhydroglucitol (1,5 AG)</title>
        <time_frame>Baseline (Initiation), Endpoint (Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Change From Baseline to Endpoint in 1,5 Anhydroglucitol (1,5 AG)</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>micrograms per milliliter (ug/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="925"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="4.85"/>
                    <measurement group_id="O2" value="5.25" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline, country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Incremental Change From Baseline in Body Weight</title>
        <time_frame>Baseline (Initiation), Weeks 6, 12, 18, 24, Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Gargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Incremental Change From Baseline in Body Weight</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1016"/>
                <count group_id="O2" value="1008"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Week 6 (n=1008,995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="2.48"/>
                    <measurement group_id="O2" value="1.66" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (n=970, 960)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="3.41"/>
                    <measurement group_id="O2" value="2.63" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 18 (n=943,927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="3.65"/>
                    <measurement group_id="O2" value="3.44" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 24 (n=925,911)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="4.09"/>
                    <measurement group_id="O2" value="3.76" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at endpoint (n=1016,1008)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="4.02"/>
                    <measurement group_id="O2" value="3.60" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change from baseline at Week 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change from baseline at Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change from baseline at Week 18</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change from baseline at Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change from baseline at endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Body Weight</title>
        <time_frame>Baseline (Initiation), Weeks 6, 12, 18, 24, Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Body Weight</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1046"/>
                <count group_id="O2" value="1044"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Actual weight at Baseline (n=1046,1044)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.23" spread="20.78"/>
                    <measurement group_id="O2" value="88.84" spread="20.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual weight at Week 6 (n=1008,995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.24" spread="20.88"/>
                    <measurement group_id="O2" value="90.63" spread="20.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual weight at Week 12 (n=970,960)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.80" spread="20.96"/>
                    <measurement group_id="O2" value="91.79" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual weight at Week 18 (n=943,927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.33" spread="21.17"/>
                    <measurement group_id="O2" value="92.46" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual weight at Week 24 (n=925,911)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.78" spread="21.46"/>
                    <measurement group_id="O2" value="92.63" spread="21.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual weight Endpoint (n=1016,1008)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.74" spread="21.36"/>
                    <measurement group_id="O2" value="92.67" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.497</p_value>
            <p_value_desc>P-value for Actual weight at baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Actual weight at Week 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Actual weight at Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Actual weight at Week 18.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Actual weight at Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is for Actual weight at Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes</title>
        <description>Hypoglycemia = any time participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
        <time_frame>Baseline (Initiation), Endpoint (Week 24), Overall (sum of frequencies of hypoglycemic episodes after baseline ([Week 0]).</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes</title>
          <description>Hypoglycemia = any time participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1024"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypoglycemic episodes endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall hypoglycemic episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7"/>
                    <measurement group_id="O2" value="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal hypoglycemic episodes endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3"/>
                    <measurement group_id="O2" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal hypoglycemic episodes overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4"/>
                    <measurement group_id="O2" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hypoglycemic episodes endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hypoglycemic episodes overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>P-value is for Hypoglycemic episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <p_value_desc>P-value is for Overall hypoglycemic episodes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.834</p_value>
            <p_value_desc>P-value is for Nocturnal hypoglycemic episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.585</p_value>
            <p_value_desc>P-value is for Nocturnal hypoglycemic episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <p_value_desc>P-value is for Severe hypoglycemic episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>P-value is for Severe hypoglycemic episodes overall. Initiation phase and maintenance phase are included.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Rate of Self-reported Hypoglycemic Episodes</title>
        <description>Hypoglycemia = participant feels/person observes, that participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
        <time_frame>Endpoint (Initiation: Week 24), Overall (incidence of hypoglycemic episodes after baseline [Week 0])</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Rate of Self-reported Hypoglycemic Episodes</title>
          <description>Hypoglycemia = participant feels/person observes, that participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>Episodes/participant/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1024"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nocturnal episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.42" spread="25.31"/>
                    <measurement group_id="O2" value="8.86" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80" spread="17.50"/>
                    <measurement group_id="O2" value="9.22" spread="16.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.38"/>
                    <measurement group_id="O2" value="0.09" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.31"/>
                    <measurement group_id="O2" value="0.10" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.28" spread="38.25"/>
                    <measurement group_id="O2" value="24.96" spread="39.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.14" spread="28.05"/>
                    <measurement group_id="O2" value="25.49" spread="36.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.420</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.165</p_value>
            <p_value_desc>P-value is for Severe episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <p_value_desc>P-value is for Severe episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Insulin Dose</title>
        <time_frame>Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Insulin glargine for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Lispro Low Mix (LM) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Insulin Dose</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>units/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
                <count group_id="O2" value="1036"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=994,1001)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.04"/>
                    <measurement group_id="O2" value="0.24" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=991, 987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.07"/>
                    <measurement group_id="O2" value="0.28" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=990,968)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.09"/>
                    <measurement group_id="O2" value="0.32" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=971,958)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.11"/>
                    <measurement group_id="O2" value="0.35" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=958,930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.14"/>
                    <measurement group_id="O2" value="0.38" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=998,1023)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.15"/>
                    <measurement group_id="O2" value="0.39" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=949,933)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.17"/>
                    <measurement group_id="O2" value="0.42" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=925,916)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.19"/>
                    <measurement group_id="O2" value="0.44" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=970,972)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.20"/>
                    <measurement group_id="O2" value="0.45" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (n=943,943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.22"/>
                    <measurement group_id="O2" value="0.46" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=915,920)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.23"/>
                    <measurement group_id="O2" value="0.48" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=1029,1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.23"/>
                    <measurement group_id="O2" value="0.47" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 1.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 2.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 3.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 4.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 5.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 8.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 10.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for Week 18.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age</title>
        <description>Comparison of age at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age</title>
          <description>Comparison of age at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="927"/>
                <count group_id="O2" value="906"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.21" spread="9.31"/>
                    <measurement group_id="O2" value="55.85" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin</title>
        <description>Comparison of origin at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin</title>
          <description>Comparison of origin at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="927"/>
                <count group_id="O2" value="906"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680"/>
                    <measurement group_id="O2" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African Descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East/Southeast Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country, TZD use, and Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>Comparison of HOMA-IR (surrogate markers of insulin resistance calculated from fasting insulin and glucose) at baseline between those participants who met their goal at Week 24 and those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%). HOMA-IR = fasting insulin (milliunits per milliliter) * fasting plasma glucose (millimoles per liter) / 22.5.</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>Comparison of HOMA-IR (surrogate markers of insulin resistance calculated from fasting insulin and glucose) at baseline between those participants who met their goal at Week 24 and those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%). HOMA-IR = fasting insulin (milliunits per milliliter) * fasting plasma glucose (millimoles per liter) / 22.5.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="877"/>
                <count group_id="O2" value="859"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="3.73"/>
                    <measurement group_id="O2" value="5.45" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c</title>
        <description>Comparison of baseline HbA1c between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c</title>
          <description>Comparison of baseline HbA1c between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
                <count group_id="O2" value="885"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="1.13"/>
                    <measurement group_id="O2" value="9.40" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use and Sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group</title>
        <description>Comparison of baseline HbA1c percentage group (&lt;8.5,&gt;=8.5) between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group</title>
          <description>Comparison of baseline HbA1c percentage group (&lt;8.5,&gt;=8.5) between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
                <count group_id="O2" value="885"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;8.5% HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=8.5% HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451"/>
                    <measurement group_id="O2" value="665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 1,5 AG</title>
        <description>Comparison of 1,5 AG between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 1,5 AG</title>
          <description>Comparison of 1,5 AG between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>micrograms per milliliter (ug/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="889"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="4.37"/>
                    <measurement group_id="O2" value="4.28" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose, Post Meals Blood Glucose, Average of All Blood Glucose, and Fasting Blood Glucose</title>
        <description>Comparison of pre meals blood glucose, post meals blood glucose, average of all blood glucose, and fasting blood glucose between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose, Post Meals Blood Glucose, Average of All Blood Glucose, and Fasting Blood Glucose</title>
          <description>Comparison of pre meals blood glucose, post meals blood glucose, average of all blood glucose, and fasting blood glucose between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="894"/>
                <count group_id="O2" value="866"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Meals Blood Glucose (n=892,866)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.47" spread="49.67"/>
                    <measurement group_id="O2" value="209.86" spread="59.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Meals Blood Glucose (n=891,865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.87" spread="54.58"/>
                    <measurement group_id="O2" value="252.90" spread="60.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average of All Blood Glucose (n=894,866)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.43" spread="50.05"/>
                    <measurement group_id="O2" value="227.77" spread="57.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting Blood Glucose (n=891,864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.04" spread="48.73"/>
                    <measurement group_id="O2" value="201.22" spread="57.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Pre Meals Blood Glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Post Meals Blood Glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Average of All Blood Glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Fasting Blood Glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with met goal/did not meet goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline</title>
        <description>Comparison of oral diabetes medication at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
        <time_frame>Endpoint (Initiation: Week 24)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Met Goal</title>
          </group>
          <group group_id="O2">
            <title>Did Not Meet Goal</title>
          </group>
        </group_list>
        <measure>
          <title>INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline</title>
          <description>Comparison of oral diabetes medication at baseline between those participants who met their goal at Week 24 versus those who did not meet their goal at Week 24 (goal HbA1c ≤7.0%).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Initiation baseline: Week 0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="917"/>
                <count group_id="O2" value="901"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sulfonylurea/Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563"/>
                    <measurement group_id="O2" value="631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TZD/Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfonylurea/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with 3 drugs (Sulfonylurea/TZD/Metformin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Sulfonylurea/Metformin.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for TZD/Metformin.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.969</p_value>
            <p_value_desc>P-value is for Sulfonylurea/TZD.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.225</p_value>
            <p_value_desc>P-value is for Patients with 3 drugs (Sulfonylurea/TZD/Metformin).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: HbA1c at Specified Visits and Endpoint</title>
        <time_frame>Baseline (Week 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: HbA1c at Specified Visits and Endpoint</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=415,464)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="1.08"/>
                    <measurement group_id="O2" value="8.69" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=412,465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.56"/>
                    <measurement group_id="O2" value="6.75" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=418,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="0.40"/>
                    <measurement group_id="O2" value="6.49" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=403,460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.72" spread="0.60"/>
                    <measurement group_id="O2" value="6.71" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=395,443)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="0.70"/>
                    <measurement group_id="O2" value="6.80" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=332,403)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="0.63"/>
                    <measurement group_id="O2" value="6.83" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=305,363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="0.68"/>
                    <measurement group_id="O2" value="6.79" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=268,312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="0.60"/>
                    <measurement group_id="O2" value="6.74" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=242,291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="0.64"/>
                    <measurement group_id="O2" value="6.73" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=219,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="0.63"/>
                    <measurement group_id="O2" value="6.72" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=204,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="0.65"/>
                    <measurement group_id="O2" value="6.75" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=414,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.20" spread="0.82"/>
                    <measurement group_id="O2" value="7.10" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <p_value_desc>P-value is for Week 0.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANCOVA used with treatment, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.657</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.595</p_value>
            <p_value_desc>P-value is for Week 36.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <p_value_desc>P-value for Week 48.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.551</p_value>
            <p_value_desc>P-value for Week 60.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.779</p_value>
            <p_value_desc>P-value is for Week 72.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <p_value_desc>P-value is for Week 84.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>P-value for Week 96.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P-value is for Week 108.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>P-value is for Week 120.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions</title>
        <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
        <time_frame>Baseline (Maintenance: Week 24), Endpoint (LOCF) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions</title>
          <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline mean fasting blood glucose (n=403,456)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.90" spread="48.90"/>
                    <measurement group_id="O2" value="187.12" spread="48.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint mean fasting blood glucose (n=372,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.50" spread="29.04"/>
                    <measurement group_id="O2" value="127.92" spread="32.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM 2-hour (hr) postprandial (n=398,455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.62" spread="58.58"/>
                    <measurement group_id="O2" value="243.55" spread="61.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint AM 2-hour postprandial (n=368,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.94" spread="44.29"/>
                    <measurement group_id="O2" value="161.37" spread="44.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline midday premeal blood glucose (n=400,454)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.21" spread="61.66"/>
                    <measurement group_id="O2" value="192.02" spread="60.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint midday premeal blood glucose (n=370,425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.25" spread="38.28"/>
                    <measurement group_id="O2" value="126.42" spread="37.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline midday 2hr postprandial (n=397,456)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.67" spread="61.90"/>
                    <measurement group_id="O2" value="218.54" spread="60.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint midday 2hr postprandial (n=370,424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.81" spread="42.21"/>
                    <measurement group_id="O2" value="158.58" spread="40.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PM pre-meal blood glucose (n=402,455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.06" spread="57.83"/>
                    <measurement group_id="O2" value="187.92" spread="56.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint PM pre-meal blood glucose (n=371,425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.58" spread="37.22"/>
                    <measurement group_id="O2" value="133.15" spread="37.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PM 2hr postprandial (n=399,455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.83" spread="62.70"/>
                    <measurement group_id="O2" value="223.02" spread="60.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint PM 2hr postprandial (n=369,425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.66" spread="43.81"/>
                    <measurement group_id="O2" value="156.48" spread="44.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 3AM blood glucose (n=393,450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.36" spread="59.87"/>
                    <measurement group_id="O2" value="183.18" spread="57.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint 3AM blood glucose (n=363,419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.05" spread="34.33"/>
                    <measurement group_id="O2" value="123.43" spread="35.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM 2hr excursion (n=397,455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.63" spread="44.06"/>
                    <measurement group_id="O2" value="56.96" spread="45.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint AM 2hr excursion (n=368,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.69" spread="39.41"/>
                    <measurement group_id="O2" value="33.61" spread="38.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline midday 2hr excursion (n=395,452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.13" spread="46.67"/>
                    <measurement group_id="O2" value="27.02" spread="43.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint midday 2hr excursion (n=370,423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="37.38"/>
                    <measurement group_id="O2" value="32.03" spread="38.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PM 2hr excursion (n=398,453)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.87" spread="42.37"/>
                    <measurement group_id="O2" value="34.78" spread="44.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint PM 2hr excursion (n=369,424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.24" spread="37.55"/>
                    <measurement group_id="O2" value="23.45" spread="41.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all meal time excursions (n=402,455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.36" spread="27.26"/>
                    <measurement group_id="O2" value="39.65" spread="25.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint mean all meal time excursions (n=370,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.32" spread="26.25"/>
                    <measurement group_id="O2" value="29.81" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean of all 2hr postprandial (n=402,457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.52" spread="54.01"/>
                    <measurement group_id="O2" value="228.39" spread="53.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint mean of all 2hr postprandial (n=370,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.17" spread="36.30"/>
                    <measurement group_id="O2" value="158.91" spread="36.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all premeal (n=404,456)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.46" spread="50.02"/>
                    <measurement group_id="O2" value="188.95" spread="48.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint mean all premeal (n=372,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.61" spread="28.40"/>
                    <measurement group_id="O2" value="129.16" spread="29.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline combined AM/PM 2hr postprandial (402,457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.82" spread="55.31"/>
                    <measurement group_id="O2" value="233.25" spread="55.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint combined AM/PM 2hr postprandial (370,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.34" spread="38.28"/>
                    <measurement group_id="O2" value="158.97" spread="38.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AM/PM 2hr postprandial excursion (402,455</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.46" spread="32.72"/>
                    <measurement group_id="O2" value="45.80" spread="33.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint AM/PM 2hr postprandial excursion (370,426</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.76" spread="32.01"/>
                    <measurement group_id="O2" value="28.69" spread="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all blood glucose values (n=405,457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.01" spread="49.91"/>
                    <measurement group_id="O2" value="205.17" spread="48.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint mean all blood glucose values (n=372,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.94" spread="29.16"/>
                    <measurement group_id="O2" value="141.01" spread="28.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <p_value_desc>P-value for Baseline mean fasting blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint mean fasting blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.897</p_value>
            <p_value_desc>P-value is for Baseline AM 2-hour (hr) postprandial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.138</p_value>
            <p_value_desc>P-value is for Endpoint AM 2-hour postprandial.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.867</p_value>
            <p_value_desc>P-value is for Baseline midday premeal blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>P-value is for Endpoint midday premeal blood.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.792</p_value>
            <p_value_desc>P-value is for Baseline midday 2hr postprandial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.510</p_value>
            <p_value_desc>P-value is for Endpoint midday 2hr postprandial.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.535</p_value>
            <p_value_desc>P-value is for Baseline PM pre-meal blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.517</p_value>
            <p_value_desc>P-value is for Endpoint PM pre-meal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.869</p_value>
            <p_value_desc>P-value is for Baseline PM 2hr postprandial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint PM 2hr postprandial.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.164</p_value>
            <p_value_desc>P-value is for Baseline 3AM blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <p_value_desc>P-value is for Endpoint 3AM blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <p_value_desc>P-value is for Baseline AM 2hr excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint AM 2hr excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.589</p_value>
            <p_value_desc>P-value is for Baseline midday 2hr excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.161</p_value>
            <p_value_desc>P-value is for Endpoint midday 2hr excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <p_value_desc>P-value is for Baseline PM 2hr excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint PM 2hr excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <p_value_desc>P-value is for Baseline mean all meal time excursions.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint mean all meal time excursions.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.956</p_value>
            <p_value_desc>P-value is for Baseline mean of all 2hr postprandial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value is for Endpoint mean of all 2hr postprandial.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.445</p_value>
            <p_value_desc>P-value is for Baseline mean all premeal.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <p_value_desc>P-value is for Endpoint mean all premeal.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.848</p_value>
            <p_value_desc>P-value is for Baseline combined AM/PM 2hr postprandial.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is for Endpoint combined AM/PM 2hr postprandial.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <p_value_desc>P-value is for Baseline AM/PM 2hr postprandial excursion.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint AM/PM 2hr postprandial excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <p_value_desc>P-value is for Baseline mean all blood glucose values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <p_value_desc>P-value is for Endpoint mean all blood glucose values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD + Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Rate of Increase in HbA1c</title>
        <description>Rate of increase: HbA1c change/time period (month).</description>
        <time_frame>Endpoint (LOCF) (Maintenance: up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Rate of Increase in HbA1c</title>
          <description>Rate of increase: HbA1c change/time period (month).</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>HbA1c percent increase per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.08"/>
                    <measurement group_id="O2" value="0.05" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.300</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, Baseline HbA1c, country, TZD use, and sulfo use in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt;7.0, and HbA1c &lt; or = 6.5%</title>
        <time_frame>Endpoint (LOCF) (Maintenance: up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt;7.0, and HbA1c &lt; or = 6.5%</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1"/>
                    <measurement group_id="O2" value="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <p_value_desc>P-value for &lt;=7.0%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <p_value_desc>P-value is for &lt;7.0%</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.235</p_value>
            <p_value_desc>P-value is for &lt;=6.5%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Incremental Change From Baseline in Body Weight</title>
        <time_frame>Baseline (Week 0), Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Incremental Change From Baseline in Body Weight</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=419,473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.56" spread="20.12"/>
                    <measurement group_id="O2" value="88.62" spread="19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 24 (n=417,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="3.79"/>
                    <measurement group_id="O2" value="3.68" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 36 (n=411,465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="4.22"/>
                    <measurement group_id="O2" value="4.56" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 48 (n=399,460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="4.46"/>
                    <measurement group_id="O2" value="4.82" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 60 (n=362,414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="4.76"/>
                    <measurement group_id="O2" value="5.13" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 72 (n=315,372)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="5.15"/>
                    <measurement group_id="O2" value="5.40" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 84 (n=281,327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="5.20"/>
                    <measurement group_id="O2" value="5.84" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 96 (n=248,297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="5.35"/>
                    <measurement group_id="O2" value="5.60" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 108 (n=228,268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="5.65"/>
                    <measurement group_id="O2" value="5.57" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 120 (n=204,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="5.47"/>
                    <measurement group_id="O2" value="5.48" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Endpoint (n=414,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="5.60"/>
                    <measurement group_id="O2" value="5.40" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 36.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 48.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 60.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 72.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 84.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 96.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 108</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is for Change from baseline at Week 120.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Change from baseline at Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Response = Treatment + Baseline + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Body Weight</title>
        <time_frame>Baseline (Week 0), Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Body Weight</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=419,473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.56" spread="20.12"/>
                    <measurement group_id="O2" value="88.62" spread="19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=417, 470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.64" spread="20.53"/>
                    <measurement group_id="O2" value="92.35" spread="19.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=411, 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.13" spread="20.68"/>
                    <measurement group_id="O2" value="93.24" spread="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=399,460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.23" spread="20.53"/>
                    <measurement group_id="O2" value="93.57" spread="19.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=362,414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.17" spread="20.60"/>
                    <measurement group_id="O2" value="94.57" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=315,372)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.62" spread="20.40"/>
                    <measurement group_id="O2" value="95.50" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=281,327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.46" spread="20.56"/>
                    <measurement group_id="O2" value="95.63" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=248, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.33" spread="20.14"/>
                    <measurement group_id="O2" value="95.34" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=228,268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.39" spread="20.23"/>
                    <measurement group_id="O2" value="95.07" spread="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=204,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.99" spread="20.22"/>
                    <measurement group_id="O2" value="94.82" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=414,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.14" spread="21.04"/>
                    <measurement group_id="O2" value="94.01" spread="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 36.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 48.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 60.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 72.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 84.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 96.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 108.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is for Week 120.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use + Sulfo Use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Insulin Dose</title>
        <time_frame>Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Insulin Dose</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>units/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=418,473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.19"/>
                    <measurement group_id="O2" value="0.43" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=415,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.19"/>
                    <measurement group_id="O2" value="0.44" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=407,464)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.20"/>
                    <measurement group_id="O2" value="0.44" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (n=364,419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.19"/>
                    <measurement group_id="O2" value="0.44" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=317,374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.20"/>
                    <measurement group_id="O2" value="0.44" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (n=284,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.20"/>
                    <measurement group_id="O2" value="0.44" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (n=251,303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.21"/>
                    <measurement group_id="O2" value="0.44" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 (n=233,273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.20"/>
                    <measurement group_id="O2" value="0.43" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 (n=205,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.20"/>
                    <measurement group_id="O2" value="0.44" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=416,472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.21"/>
                    <measurement group_id="O2" value="0.45" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 36.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 48.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 60.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 72.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 84.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 96.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 108.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 120.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model: Treatment + Country + TZD use + sulfonylurea use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes</title>
        <description>Hypoglycemia = participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years), Overall (incidence of hypoglycemic episodes after baseline (Week 0)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes</title>
          <description>Hypoglycemia = participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall hypoglycemic episodes endpoint (n=415,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall hypoglycemic episodes (n=419,473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes endpoint (n=415,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes overall (n=419,473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes endpoint (n=415,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes overall (n=419,473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <p_value_desc>P-value is for Overall hypoglycemic episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-Value for Overall hypoglycemia episodes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.397</p_value>
            <p_value_desc>P-value is for Nocturnal episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <p_value_desc>P-value is for Nocturnal episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.893</p_value>
            <p_value_desc>P-value is for Severe episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <p_value_desc>P-value is for Severe episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes</title>
        <description>Hypoglycemia = participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years), Overall (incidence of hypoglycemic episodes after baseline [Week 0])</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes</title>
          <description>Hypoglycemia = participant feels/person observes that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>episodes/participant/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypoglycemia episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.41" spread="34.78"/>
                    <measurement group_id="O2" value="18.56" spread="35.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.80" spread="26.77"/>
                    <measurement group_id="O2" value="26.08" spread="31.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.70" spread="19.36"/>
                    <measurement group_id="O2" value="5.86" spread="15.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.77" spread="15.01"/>
                    <measurement group_id="O2" value="8.02" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="4.43"/>
                    <measurement group_id="O2" value="0.03" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="2.12"/>
                    <measurement group_id="O2" value="0.03" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.497</p_value>
            <p_value_desc>P-value for Hypoglycemia episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <p_value_desc>P-value is for Severe episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <p_value_desc>P-value is for Severe episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Change From Baseline in 1,5-Anhydroglucitol</title>
        <time_frame>Baseline (Maintenance: Week 24), Endpoint (LOCF) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Change From Baseline in 1,5-Anhydroglucitol</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="4.34"/>
                    <measurement group_id="O2" value="5.87" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.48" spread="6.26"/>
                    <measurement group_id="O2" value="11.71" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="5.28"/>
                    <measurement group_id="O2" value="5.84" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is for Change.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline, country, TZD use and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Change From Baseline to Endpoint in HbA1c</title>
        <time_frame>Baseline (Week 0), Week 24, Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Initiation Phase: Insulin glargine for 24 weeks. Maintenance Phase: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Low Mix</title>
            <description>Initiation Phase: Lispro Low Mix (LM) for 24 weeks. Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Change From Baseline to Endpoint in HbA1c</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline at Week 0 (n=415,464)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="1.08"/>
                    <measurement group_id="O2" value="8.69" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to endpoint (n=409,462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.18"/>
                    <measurement group_id="O2" value="-1.59" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Week 24 to Week 120 endpoint (n=412,469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.11"/>
                    <measurement group_id="O2" value="0.61" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <p_value_desc>P-value is for Baseline at Week 0.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA used with treatment, country, TZD use and Sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-Value is for Change from baseline to endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, Baseline HbA1c, country, TZD use and sulfo use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>P-value is for Change Week 24 to Week 120 endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA used with treatment, Baseline HbA1c, country, TZD use and sulfo use in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes</title>
        <description>Comparison of duration of diabetes at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes</title>
          <description>Comparison of duration of diabetes at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="4.92"/>
                    <measurement group_id="O2" value="9.70" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes</title>
        <description>Comparison of duration of diabetes at baseline between those participants taking lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes</title>
          <description>Comparison of duration of diabetes at baseline between those participants taking lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="6.24"/>
                    <measurement group_id="O2" value="9.87" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>ANOVA</method>
            <method_desc>From ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group</title>
        <description>Comparison of duration of diabetes group (&lt;10, 10-&lt;20, &gt;=20 years) at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group</title>
          <description>Comparison of duration of diabetes group (&lt;10, 10-&lt;20, &gt;=20 years) at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less than 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 years to less than 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 or more years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country, TZD use, and Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group</title>
        <description>Comparison of duration of diabetes group (&lt;10, 10-&lt;20, &gt;=20 years) at baseline between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group</title>
          <description>Comparison of duration of diabetes group (&lt;10, 10-&lt;20, &gt;=20 years) at baseline between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 to &lt;20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c</title>
        <description>Comparison of baseline HbA1c between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c</title>
          <description>Comparison of baseline HbA1c between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="0.94"/>
                    <measurement group_id="O2" value="8.77" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c</title>
        <description>Comparison of baseline HbA1c between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c</title>
          <description>Comparison of baseline HbA1c between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.54" spread="1.13"/>
                    <measurement group_id="O2" value="8.80" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group</title>
        <description>Comparison of baseline HbA1c group (&lt;8.5,&gt;=8.5) between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group</title>
          <description>Comparison of baseline HbA1c group (&lt;8.5,&gt;=8.5) between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less than 8.5% HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=8.5% HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group</title>
        <description>Comparison of baseline HbA1c group (&lt;8.5,&gt;=8.5) between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group</title>
          <description>Comparison of baseline HbA1c group (&lt;8.5,&gt;=8.5) between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less than 8.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.5 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country, TZD use, and sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline</title>
        <description>Comparison of oral diabetes medication at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline</title>
          <description>Comparison of oral diabetes medication at baseline between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sulfonylurea/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfonylurea/metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfonylurea/metformin/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <p_value_desc>P-value is for Sulfonylurea/TZD.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>P-value is for Sulfonylurea/metformin.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.132</p_value>
            <p_value_desc>P-value is for Metformin/TZD.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.849</p_value>
            <p_value_desc>P-value is for Sulfonylurea/metformin/TZD.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline</title>
        <description>Comparison of oral diabetes medication at baseline between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline</title>
          <description>Comparison of oral diabetes medication at baseline between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sulfonylurea/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfonylurea/metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfonylurea/metformin/TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is for Sulfonylurea/TZD</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>P-value is for Sulfonylurea/metformin.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.258</p_value>
            <p_value_desc>P-value is for Metformin/TZD.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.848</p_value>
            <p_value_desc>P-value is for Sulfonylurea/metformin/TZD.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by country only.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG</title>
        <description>Comparison of baseline 1,5 AG between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG</title>
          <description>Comparison of baseline 1,5 AG between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="4.60"/>
                    <measurement group_id="O2" value="5.39" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG</title>
        <description>Comparison of baseline 1,5 AG between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG</title>
          <description>Comparison of baseline 1,5 AG between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="4.17"/>
                    <measurement group_id="O2" value="5.73" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.553</p_value>
            <method>ANOVA</method>
            <method_desc>From ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose</title>
        <description>Comparison of baseline mean of post meals blood glucose and average of all blood glucose between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose</title>
          <description>Comparison of baseline mean of post meals blood glucose and average of all blood glucose between those participants taking insulin glargine that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean of post meals blood glucose (n=141,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.28" spread="51.23"/>
                    <measurement group_id="O2" value="233.51" spread="54.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average of all blood glucose (n=141,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.60" spread="48.07"/>
                    <measurement group_id="O2" value="210.44" spread="50.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is for Mean of all post meals blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>P-value is for Average of all blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose</title>
        <description>Comparison of baseline mean of post meals blood glucose and average of all blood glucose between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
        <time_frame>Endpoint (LOCF) (Maintenance) (up to 2.5 years)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro LM Participants Who Maintained Goal</title>
          </group>
          <group group_id="O2">
            <title>Lispro LM Participants Who Did Not Maintain Goal</title>
          </group>
        </group_list>
        <measure>
          <title>MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose</title>
          <description>Comparison of baseline mean of post meals blood glucose and average of all blood glucose between those participants taking Lispro LM that maintained their HbA1c goal and those that did not. Participants who maintained goal are those who did not fail during their duration on study. Failure is defined by HbA1c &gt; 7.0% with change &gt;= 0.4% from most recent HbA1c that was &lt;=7.0%.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Maintenance baseline: Week 24.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean of post meals blood glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.98" spread="52.54"/>
                    <measurement group_id="O2" value="231.66" spread="54.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average of all blood glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.42" spread="48.42"/>
                    <measurement group_id="O2" value="207.96" spread="49.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.516</p_value>
            <p_value_desc>P-value is for Mean of post-meals blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>From ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.425</p_value>
            <p_value_desc>P-value is for Average of all blood glucose.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>From ANOVA with maintained goal/did not maintain goal, country, TZD use, and sulfo use in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint</title>
        <time_frame>Baseline (Addendum: Week 24), Endpoint (24 weeks [Week 48])</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro LM Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="171"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=174,200,171,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread="0.93"/>
                    <measurement group_id="O2" value="8.03" spread="0.95"/>
                    <measurement group_id="O3" value="8.00" spread="0.92"/>
                    <measurement group_id="O4" value="7.98" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=160,187,159,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="1.12"/>
                    <measurement group_id="O2" value="0.04" spread="1.06"/>
                    <measurement group_id="O3" value="0.19" spread="1.16"/>
                    <measurement group_id="O4" value="0.18" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.770</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.990</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.552</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt; 7.0%, and &lt; or = 6.5%</title>
        <time_frame>Endpoint (Addendum: 24 weeks [Week 48])</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro LM Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Percentage of Participants With HbA1c &lt; or = 7.0%, HbA1c &lt; 7.0%, and &lt; or = 6.5%</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="22.0"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="13.9"/>
                    <measurement group_id="O3" value="17.6"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>P-value is for &lt;=7.0%.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value is for &lt;7.0%.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.799</p_value>
            <p_value_desc>P-value is for &lt;=6.5%.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.676</p_value>
            <p_value_desc>P-value is for &lt;=7.0%.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>P-value is for &lt;7.0%.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>P-value is for &lt;=6.5%.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: 7-point SMPG Profiles</title>
        <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
        <time_frame>Endpoint (Addendum: 24 weeks [Week 48])</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus Prior Lispro LM Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Lispro Low Mix Prior Glargine Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: 7-point SMPG Profiles</title>
          <description>Abbreviations: AM = morning; BG = blood glucose; PM = evening; PP = postprandial. A postprandial excursion is defined as: 2 hour postmeal plasma glucose-premeal plasma glucose.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="183"/>
                <count group_id="O4" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean fast blood glucose (BG) (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.33" spread="35.23"/>
                    <measurement group_id="O2" value="151.15" spread="37.31"/>
                    <measurement group_id="O3" value="126.22" spread="39.00"/>
                    <measurement group_id="O4" value="139.45" spread="34.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM 2-hour postprandial (PP) BG (n=135,149,160,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.71" spread="44.90"/>
                    <measurement group_id="O2" value="170.36" spread="50.25"/>
                    <measurement group_id="O3" value="170.14" spread="49.27"/>
                    <measurement group_id="O4" value="171.40" spread="46.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midday premeal blood glucose (n=135,150,161,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.08" spread="43.93"/>
                    <measurement group_id="O2" value="145.89" spread="42.61"/>
                    <measurement group_id="O3" value="144.61" spread="41.39"/>
                    <measurement group_id="O4" value="141.87" spread="43.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midday 2-hour (hr) PP BG (n=135,149,160,176))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.24" spread="46.46"/>
                    <measurement group_id="O2" value="164.13" spread="42.17"/>
                    <measurement group_id="O3" value="167.45" spread="48.27"/>
                    <measurement group_id="O4" value="181.46" spread="53.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM premeal blood glucose (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.62" spread="41.82"/>
                    <measurement group_id="O2" value="151.96" spread="41.66"/>
                    <measurement group_id="O3" value="157.15" spread="54.22"/>
                    <measurement group_id="O4" value="153.19" spread="40.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM 2-hour postprandial BG (n=134,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.51" spread="44.42"/>
                    <measurement group_id="O2" value="172.98" spread="48.01"/>
                    <measurement group_id="O3" value="175.34" spread="53.17"/>
                    <measurement group_id="O4" value="174.94" spread="46.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 AM blood glucose (n=132,146,153,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.50" spread="40.09"/>
                    <measurement group_id="O2" value="146.30" spread="41.36"/>
                    <measurement group_id="O3" value="147.14" spread="39.99"/>
                    <measurement group_id="O4" value="139.86" spread="39.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM 2-hour BG excursion (n=135,149,160,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.30" spread="39.14"/>
                    <measurement group_id="O2" value="18.97" spread="46.88"/>
                    <measurement group_id="O3" value="24.35" spread="38.44"/>
                    <measurement group_id="O4" value="31.33" spread="43.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midday 2-hour BG excursion (n=135,148,160,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.71" spread="43.35"/>
                    <measurement group_id="O2" value="18.97" spread="41.40"/>
                    <measurement group_id="O3" value="23.30" spread="37.21"/>
                    <measurement group_id="O4" value="39.40" spread="46.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM 2-hour BG excursion (n=134,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.88" spread="38.16"/>
                    <measurement group_id="O2" value="21.14" spread="42.48"/>
                    <measurement group_id="O3" value="18.58" spread="41.86"/>
                    <measurement group_id="O4" value="21.59" spread="43.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean all mealtime excursions (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.61" spread="28.41"/>
                    <measurement group_id="O2" value="19.64" spread="27.87"/>
                    <measurement group_id="O3" value="21.82" spread="26.09"/>
                    <measurement group_id="O4" value="30.38" spread="31.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean all 2-hour PP BG (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.55" spread="38.92"/>
                    <measurement group_id="O2" value="169.14" spread="39.27"/>
                    <measurement group_id="O3" value="170.95" spread="42.89"/>
                    <measurement group_id="O4" value="175.61" spread="42.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean all premeal blood glucose (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.68" spread="32.85"/>
                    <measurement group_id="O2" value="149.67" spread="33.20"/>
                    <measurement group_id="O3" value="149.04" spread="38.35"/>
                    <measurement group_id="O4" value="144.85" spread="32.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean combined AM/PM 2hr PP BG (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.04" spread="39.98"/>
                    <measurement group_id="O2" value="171.65" spread="43.23"/>
                    <measurement group_id="O3" value="172.73" spread="45.15"/>
                    <measurement group_id="O4" value="172.88" spread="41.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean AM/PM 2hr BG excursion (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.74" spread="30.40"/>
                    <measurement group_id="O2" value="20.06" spread="34.62"/>
                    <measurement group_id="O3" value="21.42" spread="32.09"/>
                    <measurement group_id="O4" value="26.45" spread="33.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean all BG values (n=135,150,161,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.41" spread="33.04"/>
                    <measurement group_id="O2" value="157.52" spread="32.67"/>
                    <measurement group_id="O3" value="158.33" spread="37.89"/>
                    <measurement group_id="O4" value="157.41" spread="33.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean all premeals BG (n=152,161,183,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.91" spread="38.96"/>
                    <measurement group_id="O2" value="149.50" spread="34.82"/>
                    <measurement group_id="O3" value="146.64" spread="39.89"/>
                    <measurement group_id="O4" value="146.01" spread="34.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline mean of postmeal BG (n=152,161,182,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.82" spread="45.13"/>
                    <measurement group_id="O2" value="181.18" spread="43.49"/>
                    <measurement group_id="O3" value="186.19" spread="46.23"/>
                    <measurement group_id="O4" value="185.62" spread="41.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline average of all BG (n=152,161,183,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.02" spread="39.20"/>
                    <measurement group_id="O2" value="162.18" spread="35.22"/>
                    <measurement group_id="O3" value="163.19" spread="40.08"/>
                    <measurement group_id="O4" value="163.20" spread="34.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline fasting glucose (n=152,161,183,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.93" spread="39.46"/>
                    <measurement group_id="O2" value="143.99" spread="34.91"/>
                    <measurement group_id="O3" value="131.54" spread="42.16"/>
                    <measurement group_id="O4" value="131.02" spread="34.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <p_value_desc>P-value is for Mean fast blood glucose (BG).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.305</p_value>
            <p_value_desc>P-value is for AM 2-hour postprandial (PP) BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.842</p_value>
            <p_value_desc>P-value is for Midday premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.917</p_value>
            <p_value_desc>P-value is for Midday 2-hour (hr) PP BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.648</p_value>
            <p_value_desc>P-value is for PM premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.613</p_value>
            <p_value_desc>P-value is for PM 2-hour postprandial BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.813</p_value>
            <p_value_desc>P-value is for 3 AM blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>P-value is for AM 2-hour BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.933</p_value>
            <p_value_desc>P-value is for Midday 2-hour BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <p_value_desc>P-value is for PM 2-hour BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <p_value_desc>P-value is for Mean all mealtime excursions.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.573</p_value>
            <p_value_desc>P-value is for Mean all 2-hour PP BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <p_value_desc>P-value is for Mean all premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.372</p_value>
            <p_value_desc>P-value is for Mean combined AM/PM 2hr PP BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.516</p_value>
            <p_value_desc>P-value is for Mean AM/PM 2hr BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.639</p_value>
            <p_value_desc>P-value is for Mean all BG values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <p_value_desc>P-value is for Mean fast blood glucose (BG).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <p_value_desc>P-value is for AM 2-hour postprandial (PP) BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <p_value_desc>P-value is for Midday premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is for Midday 2-hour (hr) PP BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.951</p_value>
            <p_value_desc>P-value is for PM premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.580</p_value>
            <p_value_desc>P-value is for PM 2-hour postprandial BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <p_value_desc>P-value is for 3 AM blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <p_value_desc>P-value is for AM 2-hour BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Midday 2-hour BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.542</p_value>
            <p_value_desc>P-value is for PM 2-hour BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is for Mean all mealtime excursions.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <p_value_desc>P-value is for Mean all 2-hour PP BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.487</p_value>
            <p_value_desc>P-value is for Mean all premeal blood glucose.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.491</p_value>
            <p_value_desc>P-value is for Mean combined AM/PM 2hr PP BG.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <p_value_desc>P-value is for Mean AM/PM 2hr BG excursion.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.861</p_value>
            <p_value_desc>P-value is for Mean all BG values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Incremental Change From Baseline in Body Weight</title>
        <time_frame>Baseline (Addendum: Week 24), Weeks 6 (30 Weeks), 12 (36 Weeks), 24 (48 Weeks), Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus Prior Lispro LM Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Lispro Low Mix Prior Glargine Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Incremental Change From Baseline in Body Weight</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=170,173,198,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.85" spread="23.41"/>
                    <measurement group_id="O2" value="93.63" spread="24.21"/>
                    <measurement group_id="O3" value="89.25" spread="21.62"/>
                    <measurement group_id="O4" value="90.09" spread="23.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 change (n=161,162,183,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="2.78"/>
                    <measurement group_id="O2" value="0.28" spread="1.76"/>
                    <measurement group_id="O3" value="0.32" spread="2.15"/>
                    <measurement group_id="O4" value="0.64" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 change (n=150,158,173,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="2.61"/>
                    <measurement group_id="O2" value="0.54" spread="2.36"/>
                    <measurement group_id="O3" value="0.27" spread="3.31"/>
                    <measurement group_id="O4" value="0.83" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 change (n=144,151,163,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="3.01"/>
                    <measurement group_id="O2" value="0.73" spread="2.85"/>
                    <measurement group_id="O3" value="1.03" spread="3.24"/>
                    <measurement group_id="O4" value="1.51" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint change (n=163,169,191,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="3.46"/>
                    <measurement group_id="O2" value="0.55" spread="2.85"/>
                    <measurement group_id="O3" value="0.86" spread="3.41"/>
                    <measurement group_id="O4" value="1.42" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.745</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.467</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.575</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.726</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Body Weight</title>
        <time_frame>Baseline (Addendum Week 24), Weeks 6 (30 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus Prior Lispro LM Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Lispro Low Mix Prior Glargine Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Body Weight</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=170,173,198,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.85" spread="23.41"/>
                    <measurement group_id="O2" value="93.63" spread="24.21"/>
                    <measurement group_id="O3" value="89.25" spread="21.62"/>
                    <measurement group_id="O4" value="90.09" spread="23.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=162,163,184,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.53" spread="23.33"/>
                    <measurement group_id="O2" value="93.71" spread="24.82"/>
                    <measurement group_id="O3" value="89.66" spread="21.97"/>
                    <measurement group_id="O4" value="89.85" spread="22.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=151,158,174,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.59" spread="22.88"/>
                    <measurement group_id="O2" value="94.60" spread="25.08"/>
                    <measurement group_id="O3" value="89.62" spread="22.04"/>
                    <measurement group_id="O4" value="91.19" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=145,151,164,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.92" spread="23.32"/>
                    <measurement group_id="O2" value="94.18" spread="24.99"/>
                    <measurement group_id="O3" value="89.80" spread="21.95"/>
                    <measurement group_id="O4" value="91.22" spread="23.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=164,170,192,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.40" spread="23.67"/>
                    <measurement group_id="O2" value="94.09" spread="24.65"/>
                    <measurement group_id="O3" value="90.09" spread="21.95"/>
                    <measurement group_id="O4" value="91.45" spread="23.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.467</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, and TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.575</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.726</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.745</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, and TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Insulin Dose</title>
        <time_frame>Baseline (Addendum: Week 24), Weeks 1 (25 weeks), 2 (26 weeks), 3 (27 weeks), 4 (28 weeks), 5 (25 weeks), 6 (26 weeks), 8 (32 weeks), 10 (34 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus Prior Lispro LM Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Lispro Low Mix Prior Glargine Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Insulin Dose</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>units/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=171,174,199,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.26"/>
                    <measurement group_id="O2" value="0.55" spread="0.25"/>
                    <measurement group_id="O3" value="0.46" spread="0.27"/>
                    <measurement group_id="O4" value="0.46" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=152,158,183,183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.26"/>
                    <measurement group_id="O2" value="0.57" spread="0.25"/>
                    <measurement group_id="O3" value="0.49" spread="0.27"/>
                    <measurement group_id="O4" value="0.49" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=147,159,180,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.29"/>
                    <measurement group_id="O2" value="0.59" spread="0.26"/>
                    <measurement group_id="O3" value="0.54" spread="0.29"/>
                    <measurement group_id="O4" value="0.53" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=149,158,179,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.28"/>
                    <measurement group_id="O2" value="0.64" spread="0.26"/>
                    <measurement group_id="O3" value="0.57" spread="0.28"/>
                    <measurement group_id="O4" value="0.58" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=145,157,178,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.29"/>
                    <measurement group_id="O2" value="0.67" spread="0.27"/>
                    <measurement group_id="O3" value="0.63" spread="0.34"/>
                    <measurement group_id="O4" value="0.61" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=148,153,172,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.29"/>
                    <measurement group_id="O2" value="0.70" spread="0.28"/>
                    <measurement group_id="O3" value="0.65" spread="0.34"/>
                    <measurement group_id="O4" value="0.65" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=162,168,190,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.29"/>
                    <measurement group_id="O2" value="0.72" spread="0.29"/>
                    <measurement group_id="O3" value="0.68" spread="0.37"/>
                    <measurement group_id="O4" value="0.66" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=139,154,164,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.29"/>
                    <measurement group_id="O2" value="0.75" spread="0.32"/>
                    <measurement group_id="O3" value="0.71" spread="0.38"/>
                    <measurement group_id="O4" value="0.69" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=141,152,158,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.31"/>
                    <measurement group_id="O2" value="0.77" spread="0.32"/>
                    <measurement group_id="O3" value="0.76" spread="0.43"/>
                    <measurement group_id="O4" value="0.73" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=152,161,177,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.33"/>
                    <measurement group_id="O2" value="0.79" spread="0.33"/>
                    <measurement group_id="O3" value="0.77" spread="0.42"/>
                    <measurement group_id="O4" value="0.74" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=147,151,166,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.35"/>
                    <measurement group_id="O2" value="0.80" spread="0.35"/>
                    <measurement group_id="O3" value="0.79" spread="0.45"/>
                    <measurement group_id="O4" value="0.76" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=165,170,199,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.35"/>
                    <measurement group_id="O2" value="0.79" spread="0.35"/>
                    <measurement group_id="O3" value="0.77" spread="0.43"/>
                    <measurement group_id="O4" value="0.76" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.837</p_value>
            <p_value_desc>P-value is for Week 1.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.205</p_value>
            <p_value_desc>P-value is for Week 2.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.704</p_value>
            <p_value_desc>P-value is for Week 3.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.610</p_value>
            <p_value_desc>P-value is for Week 4.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.352</p_value>
            <p_value_desc>P-value is for Week 5.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.636</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.880</p_value>
            <p_value_desc>P-value is for Week 8.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <p_value_desc>P-value is for Week 10.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.859</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.566</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.926</p_value>
            <p_value_desc>P-value is for Week 1.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.902</p_value>
            <p_value_desc>P-value is for Week 2.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <p_value_desc>P-value is for Week 3.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <p_value_desc>P-value is for Week 4.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.797</p_value>
            <p_value_desc>P-value is for Week 5.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.438</p_value>
            <p_value_desc>P-value is for Week 6.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <p_value_desc>P-value is for Week 8.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.493</p_value>
            <p_value_desc>P-value is for Week 10.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.335</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.398</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes</title>
        <description>Hypoglycemia = any time participant feels/person observes, that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
        <time_frame>Weeks 6 (Addendum: 30 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus Prior Lispro LM Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Lispro Low Mix Prior Glargine Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes</title>
          <description>Hypoglycemia = any time participant feels/person observes, that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypoglycemia episodes endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="41.5"/>
                    <measurement group_id="O3" value="34.9"/>
                    <measurement group_id="O4" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall hypoglycemia episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="56.1"/>
                    <measurement group_id="O3" value="47.9"/>
                    <measurement group_id="O4" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="20.5"/>
                    <measurement group_id="O3" value="19.3"/>
                    <measurement group_id="O4" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="27.1"/>
                    <measurement group_id="O4" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>P-value is for Overall hypoglycemia episodes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <p_value_desc>P-value is for Severe episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>P-value is for Nocturnal episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <p_value_desc>P-value is for Nocturnal episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes at endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <p_value_desc>P-value is for Overall hypoglycemia episodes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <p_value_desc>P-value is for Severe episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>P-value is for Nocturnal episodes endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is for Nocturnal episodes overall.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel statistic controlling for country and TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Rate of Self-reported Hypoglycemic Episodes</title>
        <description>Hypoglycemia = participant feels/person observes, that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
        <time_frame>Endpoint (Addendum 24 weeks), Overall (mean yearly rate of hypoglycemia during addendum phase</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro LM Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Rate of Self-reported Hypoglycemic Episodes</title>
          <description>Hypoglycemia = participant feels/person observes, that the participant is experiencing a sign/symptom they associate with hypoglycemia (such as hunger, dizziness, shakiness, light-headedness, sweating, irritability, headache, fast heart beat, confusion, etc) or a glucose measurement ≤70 mg/dL (≤3.9 mmol/L). Severe hypoglycemia = participant requires assistance. Qualified medical staff instructed the participants about the signs and symptoms of hypoglycemia.</description>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>episodes/participant/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypoglycemia episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.10" spread="20.36"/>
                    <measurement group_id="O2" value="10.11" spread="21.84"/>
                    <measurement group_id="O3" value="12.11" spread="28.20"/>
                    <measurement group_id="O4" value="11.18" spread="44.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.54" spread="18.70"/>
                    <measurement group_id="O2" value="10.73" spread="18.06"/>
                    <measurement group_id="O3" value="11.39" spread="22.75"/>
                    <measurement group_id="O4" value="9.04" spread="21.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="8.14"/>
                    <measurement group_id="O2" value="2.51" spread="7.03"/>
                    <measurement group_id="O3" value="2.37" spread="6.10"/>
                    <measurement group_id="O4" value="3.01" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="6.29"/>
                    <measurement group_id="O2" value="3.14" spread="6.58"/>
                    <measurement group_id="O3" value="2.09" spread="5.25"/>
                    <measurement group_id="O4" value="2.15" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe episodes Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.23"/>
                    <measurement group_id="O2" value="0.02" spread="0.21"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.623</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <p_value_desc>P-value is for Hypoglycemic episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.730</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.445</p_value>
            <p_value_desc>P-value is for Hypoglycemia episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.590</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.657</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <p_value_desc>P-value is for Nocturnal episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.161</p_value>
            <p_value_desc>P-value is for Severe episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <p_value_desc>P-value is for Severe episodes Overall.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Response = Treatment + Country + TZD use + Sulfo use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: Change From Baseline in 1,5-Anhydroglucitol to Week 24</title>
        <time_frame>Baseline (addendum: 24 weeks), Endpoint (24 weeks: Week 48)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus Prior Lispro LM Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Lispro Low Mix Prior Glargine Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: Change From Baseline in 1,5-Anhydroglucitol to Week 24</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=166,172,197,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="5.27"/>
                    <measurement group_id="O2" value="7.77" spread="5.01"/>
                    <measurement group_id="O3" value="7.31" spread="4.99"/>
                    <measurement group_id="O4" value="7.37" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=142,150,165,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" spread="6.27"/>
                    <measurement group_id="O2" value="7.73" spread="5.74"/>
                    <measurement group_id="O3" value="8.43" spread="6.17"/>
                    <measurement group_id="O4" value="8.14" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (n=142,150,165,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="4.40"/>
                    <measurement group_id="O2" value="-0.18" spread="4.91"/>
                    <measurement group_id="O3" value="0.90" spread="4.31"/>
                    <measurement group_id="O4" value="0.53" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.917</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.754</p_value>
            <p_value_desc>P-value for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.420</p_value>
            <p_value_desc>P-value is for Change.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline, country, and TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.514</p_value>
            <p_value_desc>P-value for Change.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline, country, and TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADDENDUM: HbA1c at Specified Visits and Endpoint</title>
        <time_frame>Baseline (Addendum: 24 weeks), Weeks 12, 24, Endpoint (24 weeks: Week 48)</time_frame>
        <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Lispro Mid Mix Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O2">
            <title>Lispro LM Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O3">
            <title>Basal Bolus Prior Lispro Low Mix Addendum</title>
            <description>Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
          <group group_id="O4">
            <title>Basal Bolus Prior Glargine Addendum</title>
            <description>Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, they could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>ADDENDUM: HbA1c at Specified Visits and Endpoint</title>
          <population>Last observation carried forward (LOCF) method was performed on the intent-to-treat (ITT) population who had at least 1 post-baseline assessment. Addendum baseline: 24 weeks: Week 48.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="171"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=174,200,171,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread="0.93"/>
                    <measurement group_id="O2" value="8.03" spread="0.95"/>
                    <measurement group_id="O3" value="8.00" spread="0.92"/>
                    <measurement group_id="O4" value="7.98" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=150,175,151,161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.11" spread="1.06"/>
                    <measurement group_id="O2" value="8.07" spread="1.20"/>
                    <measurement group_id="O3" value="8.13" spread="1.26"/>
                    <measurement group_id="O4" value="8.19" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=145,171,144,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="1.27"/>
                    <measurement group_id="O2" value="8.05" spread="1.18"/>
                    <measurement group_id="O3" value="8.19" spread="1.47"/>
                    <measurement group_id="O4" value="8.14" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n=160, 187,159,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="1.26"/>
                    <measurement group_id="O2" value="8.03" spread="1.15"/>
                    <measurement group_id="O3" value="8.16" spread="1.43"/>
                    <measurement group_id="O4" value="8.14" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.770</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.566</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.990</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.552</p_value>
            <p_value_desc>P-value is for Baseline.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with treatment, country, TZD use in model.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.377</p_value>
            <p_value_desc>P-value is for Week 24.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>P-value is for Endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response = Treatment + Baseline + Country + TZD use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This trial did not collect non-serious adverse events other than hypoglycemia; results of which are included as secondary outcome measures.</desc>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glargine Initiation</title>
        </group>
        <group group_id="E2">
          <title>Lispro LM Initiation</title>
        </group>
        <group group_id="E3">
          <title>Lispro Mid Mix Prior Lispro LM Addendum</title>
        </group>
        <group group_id="E4">
          <title>Lispro LM Prior Glargine Addendum</title>
        </group>
        <group group_id="E5">
          <title>Basal Bolus Prior Lispro LM Addendum</title>
        </group>
        <group group_id="E6">
          <title>Basal Bolus Prior Glargine Addendum</title>
        </group>
        <group group_id="E7">
          <title>Insulin Glargine Maintenance</title>
        </group>
        <group group_id="E8">
          <title>Lispro LM Maintenance</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1046"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1045"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E7" subjects_affected="48" subjects_at_risk="419"/>
                <counts group_id="E8" subjects_affected="48" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Epiploic appendagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Diabetic foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Encephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Nail bed infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Postoperative infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Operative haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Trigger finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Benign female reproductive tract neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Facial palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Catatonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="785" subjects_at_risk="1024"/>
                <counts group_id="E2" subjects_affected="826" subjects_at_risk="1026"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="111" subjects_at_risk="198"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="92" subjects_at_risk="192"/>
                <counts group_id="E7" subjects_affected="394" subjects_at_risk="419"/>
                <counts group_id="E8" subjects_affected="463" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="9994" subjects_affected="785" subjects_at_risk="1024"/>
                <counts group_id="E2" events="13164" subjects_affected="826" subjects_at_risk="1026"/>
                <counts group_id="E3" events="905" subjects_affected="96" subjects_at_risk="171"/>
                <counts group_id="E4" events="927" subjects_affected="111" subjects_at_risk="198"/>
                <counts group_id="E5" events="869" subjects_affected="88" subjects_at_risk="164"/>
                <counts group_id="E6" events="785" subjects_affected="92" subjects_at_risk="192"/>
                <counts group_id="E7" events="16861" subjects_affected="394" subjects_at_risk="419"/>
                <counts group_id="E8" events="22562" subjects_affected="463" subjects_at_risk="473"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

